🔎 Trials Near Me

Home › Kanser sa Ovary › California › Irvine

Pag-aaral pangklinika para sa Kanser sa Ovary sa Irvine, CA

Isang pag-aaral para sa Kanser sa Ovary ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Irvine. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Nagre-recruitPhase 2/3
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07001748

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Nagre-recruitPhase 1/2
  • Research Site, Irvine
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05797168

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

Nagre-recruitPhase 1
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914, Irvine
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07278336

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Nagre-recruitPhase 1/2
  • The City of Hope Orange County Lennar Foundation Cancer Center, Irvine
Edad 18 pataas · Kababaihan · Na-update Set 24, 2026 · NCT04590326

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Nagre-recruitPhase 3
  • City of Hope Lennar, Irvine
  • Kaiser Permanente Zion Medical Center, Irvine
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07213804

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Nagre-recruitPhase 1/2
  • City of Hope, Irvine, Irvine
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07109726

A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer

Nagre-recruit
  • City of Hope at Irvine Lennar, Irvine
Edad 18 pataas · Kababaihan · Na-update Ago 10, 2026 · NCT07741968

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Nagre-recruit
  • City of Hope at Irvine Lennar, Irvine
  • Kaiser Permanente-Irvine, Irvine
Edad 35 hanggang 50 · Kababaihan · Na-update Ago 7, 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Nagre-recruitPhase 3
  • Kaiser Permanente-Irvine, Irvine
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT06580314

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Nagre-recruitPhase 2
  • City of Hope Lennar, Irvine
Edad 18 hanggang 100 · Kababaihan · Na-update Hul 13, 2026 · NCT05887609

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

Nagre-recruitPhase 1/2
  • City of Hope, Irvine
Edad 18 hanggang 75 · Kababaihan · Na-update Hul 13, 2026 · NCT07322094

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Nagre-recruitObservasyonal na pag-aaral
  • Massive Bio SYNERGY-AI site, Irvine
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

Pag-aaral para sa Kanser sa Ovary sa ibang lungsod

Iba pang pag-aaral sa Irvine

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.